BreezeBio

Ryan Lee, CEO and co-founder, leads corporate strategy. The executive team also includes Chief Scientific Officer J. Rodrigo Mora, formerly VP of Immunoengineering at Moderna, and Chief Business Officer Dong Kim, who previously led business development at Mirum Pharmaceuticals and Aduro Biotech. The board includes investors from Sequoia, Eli Lilly, and Korea Investment, who provide oversight on capital allocation.

BreezeBio's core platform, NanoGalaxy, was developed in-house at UC Berkeley by co-founders Lee, Park, and Murthy. The company uses AI-directed screening to optimize nanoparticle formulations for cell-specific delivery, covering mRNA, CRISPR ribonucleoproteins, and pDNA. It holds multiple patents on polymer-based nanoparticle compositions and has disclosed collaborations with Genentech and Sarepta Therapeutics to apply its platform to specific disease areas.

BreezeBio is a venture-backed biotechnology company, not a family office. Its investors include institutional venture capital firms such as Sequoia, Eli Lilly, and Korea Investment. The company has raised multiple rounds including a Series A1 and Series B, and its board includes representatives from lead investors. It operates as a Delaware corporation with a standard biotech governance structure.

BreezeBio is a product-based biotech company, not an investment firm. It does not make fund commitments. It operates as a single-entity developer of genetic medicines, raising equity financing from institutional investors to fund its internal pipeline and platform development.

BreezeBio is a development-stage company, not a stage-based investor. It is currently advancing preclinical and clinical programs, with its lead candidate BRZ-101 for Type 1 Diabetes in preclinical development. It has not yet entered clinical trials.

BreezeBio focuses exclusively on genetic medicine delivery and has no disclosed diversification into other sectors. It avoids small-molecule drugs, traditional biologics, and medical devices. Its pipeline centers on autoimmune disease and oncology, with no announced plans in common biotech areas like infectious disease or vaccines.

BreezeBio was formerly known as GenEdit. The company rebranded in early 2026 as part of its Series B announcement (per firm press release, February 2026). The legal entity, ownership structure, and management team remained the same; the name change reflects a strategic pivot toward autoimmune disease and the BreezeBio branding.